Region — International. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  N-Acetyl Semax
Research reference — not for sale

N-Acetyl Semax

D
lead outcome
Human clinical evidence for the acetylated…
grades vary by outcome ↓
Peptide
also called — N-Acetyl Semax · NA-Semax · N-Acetyl Semax Amidate (a distinct further-modified variant — see note) · acetylated ACTH(4-7) Pro-Gly-Pro analog · INCI: none
neuro / cognitiveneuroprotection(derivative — research context only)

Research / reference — not for sale, not approved. The honest task here is to separate the parent's real (Russian) clinical standing from this derivative's near-empty molecule-specific record. The stability mechanism is real; the comparative "stronger than Semax" benefit is unproven. No dosing, reconstitution, or administration is published (intentional).

In brief

N-Acetyl Semax is an acetylated derivative of Semax, marketed as a "stronger, longer-lasting" version. N-terminal acetylation is a genuine and well-understood way to slow enzymatic breakdown, so the pharmacokinetic rationale is plausible — but that is chemistry, not a demonstrated benefit. The actual clinical record (the Russian stroke and cognition trials) is on unmodified Semax, not on this molecule, and there are no head-to-head human studies showing it outperforms the parent. It is approved nowhere. Treat the "stronger Semax" claim as an inference, not a finding.

Legal standing, by region
European Union
Not approved

Not approved; not eligible for magistral/officinal compounding (no Ph. Eur. monograph). Parent Semax is likewise unapproved in the EU.

United States
Not FDA-approved

Not FDA-approved. Sold research-use-only. Note the acetylated form is a distinct molecule from the Semax reviewed on the July 2026 PCAC agenda — the review concerned Semax, not N-Acetyl Semax.

International
Approved nowhere

No jurisdiction approves the acetylated form. Parent Semax is approved only in Russia/CIS.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Human clinical evidence for the acetylated form specifically
This is the crux: buyers infer the parent's clinical standing applies to the derivative. It does not. The acetyl form has no comparable trial base.
Essentially none. The clinical record — the Russian stroke and cognition trials — is on unmodified Semax, not on N-Acetyl Semax. · Not established for this molecule
D
Increased metabolic stability / longer half-life (mechanism)
A reasonable mechanism is not an outcome. "More stable in principle" is not "does more in a human" — the stability claim is chemistry, not a demonstrated benefit.
N-terminal acetylation is a well-understood way to slow aminopeptidase cleavage; plausible and consistent with peptide chemistry generally · Plausible pharmacokinetic rationale
C
Cognitive enhancement / neuroprotection (the marketed use)
Marketed as a "stronger, longer" Semax. The comparative claim (stronger than Semax) has no head-to-head human evidence behind it.
Extrapolated from parent Semax + anecdote; no direct RCTs on this form · Suggestive at best
D
Safety
Parent-Semax tolerability does not transfer automatically to a modified molecule.
No dedicated human safety data for the acetylated form · Unknown
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for N-Acetyl Semax changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Not the same as its namesake

N-Acetyl Semax is NOT the same molecule as Semax and is NOT graded as equivalent to it. The parent's evidence does not transfer to this derivative. This is a separate register entry precisely to avoid outcome substitution — do not treat a Semax grade as applying to the acetylated form.

Identity

N-Acetyl Semax is Semax with an acetyl group added to the N-terminus. Semax itself is a synthetic heptapeptide — the ACTH(4-7) fragment (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro extension. Acetylating the N-terminal end is a standard chemical move to block aminopeptidase cleavage, the enzymatic attack that clips peptides from that end. The intended result is a molecule that survives longer before breakdown.

Note there are two related but distinct derivatives sold under similar names: N-Acetyl Semax (N-terminal acetyl only) and N-Acetyl Semax Amidate (acetyl at the N-terminus and an amide at the C-terminus). They are not interchangeable, and neither is interchangeable with plain Semax.

The claim, and what actually backs it

The selling point is always comparative: stronger, longer-lasting, more potent than regular Semax. The first half of that — longer-lasting — has a real basis. N-terminal acetylation genuinely slows enzymatic degradation; that is settled peptide chemistry, not marketing.

The second half — stronger / more potent / does more in a person — does not. There are no head-to-head human trials comparing N-Acetyl Semax to Semax on any cognitive or neuroprotective outcome. The entire clinical record people point to — the Russian ischemic-stroke trials, the cognition and optic-nerve work — was done on unmodified Semax. Applying that record to the acetylated molecule is an assumption, and it is exactly the kind of assumption this register is built to flag: the parent's evidence is being borrowed to sell a derivative that hasn't earned it.

Mechanism (as proposed)

Like its parent, N-Acetyl Semax is proposed to upregulate BDNF/NGF signalling and modulate dopamine and serotonin systems, without triggering cortisol release (the ACTH(4-7) fragment lacks the hormonal activity of full ACTH). The acetyl modification is proposed to extend duration of action by resisting N-terminal cleavage. This is a plausible pharmacokinetic story — but a mechanism is not an outcome. "More stable in the tube" and "better in a human" are different claims, and only the first has support.

Sources — 3 cited
01(Parent compound: Institute of Molecular Genetics, Russian Academy of Sciences — Semax registration 1994. The acetylated analog has no comparable independent clinical literature; cite parent-Semax sources only where the claim is explicitly about the parent.)
02General peptide-chemistry references on N-terminal acetylation and aminopeptidase resistance (mechanistic basis for the stability claim).
03resolve:required — locate any primary literature specific to the N-acetylated (or N-acetyl amidate) form before publishing; do not cite parent-Semax trials as if they were on this molecule.
Updated 2026-08-07 (Derivative with essentially no molecule-specific clinical base — grade rests on the honest gap between the parent's record and this form's absence of one.)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
SemaxC
Peptide
DSIP (Delta Sleep-Inducing Peptide / Emideltide)C
Peptide
SelankC
Peptide
Explore by goal
Neuro & cognitive →
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.